Study Evaluating Etanercept in 3 Subtypes of Childhood Arthritis — CLIPPER

Arthritis, Juvenile Idiopathic Clinical Trial

Official title:
A 2-Part Open-Label Study to Assess the Clinical Benefit and Long-Term Safety of Etanercept in Children and Adolescents With Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, or Psoriatic Arthritis

Status Completed

Clinical Trial Summary

This study will evaluate the effect of etanercept on the clinical benefit, safety, and physical functioning (ability to function in daily life) in children and adolescent subjects with 3 subtypes of childhood arthritis.

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00962741
Study type	Interventional
Source	Pfizer
Contact
Status	Completed
Phase	Phase 3
Start date	September 2009
Completion date	January 2013

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00048542` - Study of Human Anti-TNF Monoclonal Antibody Adalimumab in Children With Polyarticular Juvenile Idiopathic Arthritis (JIA)	Phase 3
Completed	`NCT02593006` - Start Time Optimization of Biologics in Polyarticular JIA
Recruiting	`NCT02684695` - Juvenile Arthritis Quantitative Imaging
Completed	`NCT00130637` - Human Anti-Tac (Daclizumab) to Treat Juvenile Idiopathic Arthritis (JIA)-Associated Uveitis	Phase 2
Completed	`NCT01572896` - An Internet-based Self-management Program for Adolescents With Arthritis	N/A